Item 1A. Risk Factors
2K characters. Original on sec.gov · Markdown
Item 1A. Risk Factors
There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022.
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities
The following table sets forth a summary of our purchases during the quarter ended September 30, 2023, of equity securities that are registered by MPC pursuant to Section 12 of the Securities Exchange Act of 1934, as amended.
| Millions of Dollars | |||||||||||||||||||||||
| Period | Total Number of Shares Purchased | Average Price Paid per Share(a) | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(b) | |||||||||||||||||||
| 07/01/2023-07/31/2023 | 6,540,689 | $ | 122.39 | 6,540,689 | $ | 6,317 | |||||||||||||||||
| 08/01/2023-08/31/2023 | 9,831,087 | 143.64 | 9,831,087 | 4,904 | |||||||||||||||||||
| 09/01/2023-09/30/2023 | 3,871,396 | 151.84 | 3,871,396 | 4,317 | |||||||||||||||||||
| Total | 20,243,172 | 138.34 | 20,243,172 |
(a)Amounts in this column reflect the weighted average price paid for shares repurchased under our share repurchase authorizations. The weighted average price includes any commissions paid to brokers during the relevant period.
(b)On January 31, 2023, we announced that our board of directors had approved an additional $5.0 billion share repurchase authorization. On May 2, 2023, we announced that our board of directors had approved an additional $5.0 billion share repurchase authorization. On October 25, 2023, we announced that our board of directors had approved an additional $5.0 billion share repurchase authorization that is not included in the maximum remaining amount that may yet be purchased set forth in the table above. These share repurchase authorizations have no expiration date.
Previous: Item 4. Controls and Procedures · Next: Item 5. Other Information